KPTI

SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 3

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 764,147

F4 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F5 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 562,821

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011494 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,127

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011490 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,338

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011488 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,292

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 562,821

F4 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F5 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 764,147

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-009081 · doc4.xml · derivative · entry 2

Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,950

Underlying: Common Stock · 5,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009081 · doc4.xml · nonDerivative · entry 1

Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009070 · doc4.xml · derivative · entry 4

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009070 · doc4.xml · derivative · entry 3

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009070 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 770,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009070 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 569,422

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009138 · doc4.xml · derivative · entry 2

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,950

Underlying: Common Stock · 5,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009138 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · balance_after: Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2020.

SEC source: 0001209191-21-009079 · doc4.xml · derivative · entry 2

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,950

Underlying: Common Stock · 5,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009079 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · balance_after: Includes 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020.

SEC source: 0001209191-21-009073 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009073 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009073 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 569,422

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009073 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 770,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009076 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,450

Underlying: Common Stock · 8,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 32,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009076 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-064905 · doc4.xml · derivative · entry 3

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 6, 2020.

SEC source: 0001209191-20-064905 · doc4.xml · nonDerivative · entry 2

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-064905 · doc4.xml · nonDerivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-062319 · doc4.xml · derivative · entry 6

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 20,000 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 6, 2020.

SEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 5

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 4

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 3

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 2

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-061537 · doc4.xml · derivative · entry 6

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,842

Underlying: Common Stock · 58,937 shares

Expires 2027-01-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-061537 · doc4.xml · derivative · entry 5

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,876

Underlying: Common Stock · 78,124 shares

Expires 2028-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 4

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,523

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 3

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 2

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,523

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,647

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-060730 · doc4.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,800

Underlying: Common Stock · 32,800 shares

Expires 2030-11-24

F1 · derivative.exercise_date: This option was granted on November 25, 2020. The shares underlying this option vest as to one-third (1/3) of the shares on November 25, 2021 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter.

SEC source: 0001209191-20-056883 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,523

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · balance_after: Includes 646 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020.

SEC source: 0001209191-20-057054 · doc4.xml · nonDerivative · entry 2

Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 539

F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-20-057054 · doc4.xml · derivative · entry 3

Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295

Underlying: Common Stock · 765 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on October 28, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on October 28, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-057054 · doc4.xml · nonDerivative · entry 1

Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 765

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-054825 · doc4.xml · derivative · entry 6

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,779

Underlying: Common Stock · 721 shares

Expires 2027-01-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-054825 · doc4.xml · derivative · entry 5

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,250

Underlying: Common Stock · 38,550 shares

Expires 2029-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 4

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,649

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 3

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 2

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,649

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-054822 · doc4.xml · derivative · entry 6

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 6,076 shares

Expires 2020-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.